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Fabry disease, also known as Anderson-Fabry dis-ease, is an inherited X-linked disorder characterized by the absence (in men) or deficiency (in women) in 
α-galactosidase A activity that causes a progressive accu-
mulation of glycosphingolipids within lysosomes of cells in 
all the major organ systems and progressive organ damage 
that first manifests in childhood or early adulthood. The 
widely variable clinical picture includes acroparesthesia, 
cornea verticillata, and abdominal pain in childhood; angio-
keratoma, renal insufficiency, and electrocardiographic 
abnormalities in adolescence; and excessive daytime sleepi-
ness, obstructive sleep apnea, hypertension, cardiomyopa-
thy, renal failure, and stroke in adults.1–3 General anesthesia 
has been described in only 4 patients.4–6 We present 2 female 
patients with Fabry disease who required general anesthe-
sia twice for gynecological and trauma surgery, respectively, 
and discuss their perioperative management based on the 
explosion of new information in the medical literature.1–3,7–10
PATIENT 1
A 37-year-old Caucasian woman, diagnosed with Fabry 
disease at age 24 during her workup for hypertension in 
2003, presented for diagnostic laparoscopy and, subse-
quently, for laparoscopic resection of endometrial foci and 
the sigmoid colon with end-to-end anastomosis to treat 
her endometriosis. Her serum creatinine was 1.03 mg/dL 
(91 μmol/L) (elevated); her estimated glomerular filtration 
rate, 69 mL/min (decreased). Because of the limited severity 
of her symptoms, she was not undergoing enzyme replace-
ment therapy with α-galactosidase A.1,10 Her hypertension 
was treated with metoprolol. Her history was negative for 
the 4 pain phenotypes of Fabry disease (pain attacks, pain 
crises, evoked pain/hyperalgesia, and chronic pain)1,11 and 
obstructive sleep apnea.3
General anesthesia for both surgeries consisted of induc-
tion with fentanyl 3 μg/kg IV, propofol target-controlled 
infusion (TCI) 8 μg/mL IV, and rocuronium 0.6 mg/kg IV; 
maintenance with propofol and remifentanil TCI; and addi-
tional analgesia with paracetamol, metamizole, and fen-
tanyl IV. A lidocaine infusion was added to the maintenance 
regiment for the longer second surgery.7 Dexamethasone 
and ondansetron were administered to minimize postop-
erative nausea and vomiting. Neostigmine and glycopyrro-
late were administered to reverse neuromuscular block in 1 
case. Extubation was routine and uneventful, and there was 
no prolonged emergence or nothing unusual in her analge-
sic requirements.
PATIENT 2
A 67-year-old Caucasian woman, diagnosed at age 40 with 
Fabry disease during her workup for diffuse angiokerato-
mas, presented for osteosynthesis of her left ankle follow-
ing a bimalleolar fracture and, subsequently, for removal of 
osteosynthetic hardware. She suffered from chronic neuro-
pathic and myofascial pain, cardiomyopathy, hypertension, 
and renal insufficiency, but physical and echocardiographic 
signs of heart failure were absent. She was undergo-
ing enzyme replacement therapy with agalsidase alfa 
0.2 mg/kg every 2 weeks (Replagal; Shire Human Genetic 
Therapies, Inc). Her other chronic medications included 
aspirin, bisoprolol, candesartan, lercanidipine, metamizole, 
and pantoprazole.
For the first surgery, we induced anesthesia with fentanyl 
3 μg/kg IV, propofol 150 mg IV, and rocuronium 0.6 mg/kg, 
and utilized desflurane and remifentanyl for maintenance. 
Paracetamol and metamizole were used for postoperative 
pain; dexamethasone and ondansetron to minimize postop-
erative nausea. Norepinephrine 2 μg/min and ephedrine 
were required to stabilize the blood pressure. For the second 
surgery, maintenance anesthesia was changed to propofol 
TCI for additional reduction of nausea because she expe-
rienced mild nausea after the first anesthetic. Continuous 
infusion of catecholamines was not required.
DISCUSSION
Fabry disease, also known as Fabry’s disease, Anderson-
Fabry disease, α-galactosidase A deficiency, or angiokera-
toma corporis diffusum, is an X-linked lysosomal storage 
disease first described simultaneously but separately in 
1898 by dermatologists from Germany, Johannes Fabry,12 
and the United Kingdom, William Anderson. The first sign 
described by Fabry and Anderson was the dermal manifes-
tation called angiokeratoma, which can appear all over the 
body but most commonly manifests on the lower abdomen, 
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buttock, and thighs. Now early-onset renal insufficiency is 
the most common early sign leading to the diagnosis.
The production of lysosomal enzyme α-galactosidase A 
is reduced in Fabry disease because of mutation of the corre-
sponding gene on the X chromosome. Accumulation of the 
glycosphingolipid globotriaosylceramide (Gb3) results and 
causes cellular dysfunction not only in several organ sys-
tems, mainly skin, kidney, heart, lung, and brain, but also 
in the gastrointestinal tract and cornea. The injured endo-
thelial cells of small and large vessels and vascular smooth 
muscle cells cause dysfunction of the heart and brain lead-
ing to early onset of hypertension, concentric left ventricu-
lar hypertrophy without obstruction, and coronary heart 
disease, as well as vertebrobasilar artery signs and symp-
toms, excessive daytime sleepiness, and stroke. Small fiber 
neuropathy presenting as acroparesthesia of the hands and 
feet can occur as early as age 3.1
The measurement of the α-galactosidase A activity can 
be employed as a diagnostic tool in males. In females, the 
enzyme activity can be borderline or normal because of 
genotypic heterogeneity and random X chromosome deac-
tivation. Therefore, a genetic testing for pathologic muta-
tions of the GLA gene is always required in females. The 
subsequent therapy involves the substitution of recombi-
nant α-galactosidase A as well as individual treatment of 
the symptoms, and it depends on the organs harmed.
The prevalence of Fabry disease is difficult to determine, 
especially in women. Switzerland, the country from which we 
are reporting, expects a prevalence of approximately 1:6000 
to 1:40,000 (heterozygous women) and 1:40,000 to 1:60,000 
(men).1 On the other hand, neonatal genetic screening leads 
to higher values. Italy reported that 30 per 100,000 babies 
carry the mutation, while Taiwan counted 80 per 100,000.13 
Throughout all studies, men suffer more intense symptoms 
and faster progression of disease, as expected from the lack 
of a second, nonmutated X chromosome. The wide variabil-
ity of symptoms in women suggests a large number of them 
with α-galactosidase A deficiency may go undiagnosed. In 
our cases, the symptoms leading to diagnosis were early-
onset arterial hypertension and renal insufficiency in the first 
patient and angiokeratoma in the second patient. Because of 
these relatively unspecific manifestations, the real prevalence 
of Fabry disease is expected to be higher in women than the 
prevalence that common knowledge indicates.13
In consideration of the various manifestations and differ-
ences in the involvement of specific organs, the preoperative 
assessment must identify the specific pattern of symptoms 
present in the individual patient (Figure). Especially, severe 
damage to heart, brain, lung, and kidney must be sought and 
either optimized preoperatively or controlled during anes-
thesia.6 This involves the adaption of the anesthesia to the 
surgery performed and to predictable problems like trauma 
(hyperalgesia), cardiac/pulmonary distress, and potentially 
prolonged elimination (renal insufficiency). The adoption 
of a perioperative pain treatment plan is certainly of high 
value for the patient. However, there is no specific proto-
col to follow as yet, and the individual conditions of both 
patient and surgery provide a challenge in defining a gen-
eral approach. Some patients might undergo a nontraumatic 
surgery but suffer from chronic pain from their early child-
hood on.1 Others, as in our case 1, have mild symptoms but 
the surgery is traumatic. Although there are very few data 
regarding Fabry disease and general anesthesia, as men-
tioned, there is even less concerning peri- and postoperative 
pain, perhaps indicating uneventful outcome and not much 
need for adoption of specific perioperative pain protocols. 
This thesis, however, certainly requires very careful consid-
eration due to the lack of data, because we also adapted our 
treatment slightly by infusing lidocaine in 1 case.
In conclusion, we added 4 more anesthetics to the literature 
of patients with Fabry disease and brought the total to 8. The 
general anesthetics in our patients were essentially unevent-
ful because of preoperative identification of the medical issues 
experienced by patients with Fabry disease. Compared with 
equivalent patients without Fabry disease, we had to deal 
with early-onset arterial hypertension, hyperalgesia, cardio-
myopathy, and renal dysfunction. No additional or extended 
monitoring was required in any of the cases, but that would 
have been different with more severe symptoms. Enzyme 
replacement therapy did not appear to interfere with any of 
the drugs we used. Therefore, agalsidase alfa therapy should 
be continued following regular prescription when undergo-
ing general anesthesia. Fabry disease, depending on sex, age, 
and severity of the disease, shows a great variety of symp-
toms and signs that need to be looked for and assessed care-
fully before general anesthesia. However, patients with mild 
progression of the disease require only a few adjustments to 
keep them stable with a beneficial outcome.
Figure. Main manifestations of Fabry 
disease (table). The tables shows the 
symptoms commonly diagnosed in 
patients suffering from Fabry Disease. 
Bold marks indicate anesthesiologic 
relevance of the symptom.
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Written Consent
We obtained the written consent of the patients permitting 
the publication of this case report based on their medical 
data. E
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